Earendil Labs Deal History & Licensing Activity
Earendil Labs is a life sciences. Over the past three years, Earendil Labs has been involved in 9 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (8 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Gastroenterology
Earendil Labs Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Earendil Labs in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HXN-1003 | Sanofi | Bispecific Antibodies | Preclinical | license | Mar 2026 |
| WuXiTecan-2 | WuXi XDC | ADC | Preclinical | license | Mar 2026 |
| AI platform and pipeline expansion (including HXN-1001) | Sanofi | Other | Phase 2 | collaboration | Jun 2025 |
Earendil Labs Pipeline Focus
Therapeutic areas and modalities where Earendil Labs is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Earendil Labs Strategic Signals
Key indicators of Earendil Labs's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Earendil Labs's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Gastroenterology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
About Earendil Labs Licensing & Deal Activity
Earendil Labs is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, Earendil Labs ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Earendil Labs include Gastroenterology (6 deals and trials), Immunology (4 deals and trials), and Oncology (2 deals and trials). In terms of modality, Earendil Labs has shown particular interest in bispecific antibodies, adc, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Earendil Labs and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Earendil Labs's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.